An observational study in Blepharospasm, Torticollis and Strabismus, sponsored by Allergan. Completed at 1 site in Canada. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2014-09-10.
Sponsored by Allergan · Observational
The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.
Community sample
Exclusion Criteria:
Initiating treatment with BOTOX® upon entry to the project.
Other: botulinum toxin type A
Receiving ongoing treatment with BOTOX® upon entry to the project.
Other: botulinum toxin type A
There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cervical Dystonia
Cervical dystonia is a condition in which the neck muscles contract involuntarily, causing the head to turn to one side, forward or backward. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 505 days for patients with cervical dystonia.
Time frame: Baseline, SV1 (up to 505 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Blepharospasm
Blepharospasm is a condition in which the eyelids blink/close involuntarily. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 542 days for patients with blepharospasm.
Time frame: Baseline, SV1 (up to 542 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Hyperhidrosis
Hyperhidrosis is a condition causing excessive sweating, regardless of temperature or exercise. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,273 days for patients with hyperhidrosis.
Time frame: Baseline, SV1 (up to 1,273 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Cerebral Palsy
Cerebral Palsy is a disability resulting in muscular incoordination and speech disturbances. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 925 days for patients with cerebral palsy.
Time frame: Baseline, SV1 (up to 925 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Adult Focal Spasticity
Adult Focal Spasticity is a condition in which muscles are continuously tight or stiff in a certain area. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,562 days for patients with adult focal spasticity.
Time frame: Baseline, SV1 (up to 1,562 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With Facial Nerve Disorder
Facial nerve disorder is a condition causing twitching, weakness or paralysis of the face. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 765 days for patients with facial nerve disorder.
Time frame: Baseline, SV1 (up to 765 days)
Change From Baseline in the SF-6D Measure Health Utility (Quality of Life) Score Using the SF-12® Questionnaire for Patients With "Other" Disorders
"Other" disorders include focal dystonia (involuntary muscular contractions/abnormal postures), headache, pain, tics (sudden, repetitive, nonrhythmic movements/vocalizations), tremors (unintentional, rhythmic muscle movements), and other nonspecified disorders. The SF-12 is 12 questions on various health questions. Health utility is a numerical indicator of a person's preference for a given health state or health outcome. Health utility is a sub-score ranging from 0(death) to 1(perfect health) calculated from the SF-12 total score based on: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and SV1 is scheduled at the physician's discretion and was a maximum of 568 days for patients with "other" disorders.
Time frame: Baseline, SV1 (up to 568 days)
BOTOX® Dose in Patients With Cervical Dystonia
Cervical dystonia is a condition in which the neck muscles contract involuntarily, causing the head to turn to one side, forward or backward. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 505 days for patients with cervical dystonia.
Time frame: Baseline, SV1 (up to 505 days)
BOTOX® Dose in Patients With Blepharospasm
Blepharospasm is a condition in which the eyelids blink/close involuntarily. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 542 days for patients with blepharospasm.
Time frame: Baseline, SV1 (up to 542 days)
BOTOX® Dose in Patients With Hyperhidrosis
Hyperhidrosis is a condition causing excessive sweating, regardless of temperature or exercise. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,273 days for patients with hyperhidrosis.
Time frame: Baseline, SV1 (up to 1,273 days)
BOTOX® Dose in Patients With Adult Focal Spasticity
Adult Focal Spasticity is a condition in which muscles are continuously tight or stiff in a certain area. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,562 days for patients with adult focal spasticity.
Time frame: Baseline, SV1 (up to 1,562 days)
BOTOX® Dose in Patients With Cerebral Palsy
Cerebral Palsy is a disability resulting in muscular incoordination and speech disturbances. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 925 days for patients with cerebral palsy.
Time frame: Baseline, SV1 (up to 925 days)
BOTOX® Dose in Patients With Facial Nerve Disorder
Facial nerve disorder is a condition causing twitching, weakness or paralysis of the face. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 765 days for patients with facial nerve disorder.
Time frame: Baseline, SV1 (up to 765 days)
BOTOX® Dose in Patients With "Other" Disorders
"Other" disorders include focal dystonia (involuntary muscular contractions/abnormal postures), headache, pain, tics (sudden, repetitive, nonrhythmic movements/vocalizations), tremors (unintentional, rhythmic muscle movements), and other nonspecified disorders. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 568 days for patients with "other" disorders.
Time frame: Baseline, SV1 (up to 568 days)
Concurrent Procedure Resource Utilization Patterns
Resource utilization patterns are assessed in terms of concurrent procedures utilized during the study (up to 1,785 days across all indications) and are grouped by highest level term. (Note: NEC=not elsewhere classified)
Time frame: Up to 1,785 days
Concurrent Surgical Procedure Resource Utilization Patterns
Resource utilization patterns are assessed in terms of concurrent surgical procedures utilized during the study (up to 1,785 days across all indications) and are grouped by highest level term. (Note: NEC=not elsewhere classified)
Time frame: Up to 1,785 days
| Milestone | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Started | 506 | 866 |
| Completed | 115 | 404 |
| Not completed | 391 | 462 |
Cervical dystonia is a condition in which the neck muscles contract involuntarily, causing the head to turn to one side, forward or backward. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 505 days for patients with cervical dystonia.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.650 ± 0.154 | 0.676 ± 0.143 |
| Change from Baseline at SV1 (N=33,174) | 0.020 ± 0.084 | -0.001 ± 0.104 |
Blepharospasm is a condition in which the eyelids blink/close involuntarily. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 542 days for patients with blepharospasm.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.718 ± 0.122 | 0.754 ± 0.132 |
| Change from Baseline at SV1 (N=21, 51) | 0.053 ± 0.156 | 0.014 ± 0.120 |
Hyperhidrosis is a condition causing excessive sweating, regardless of temperature or exercise. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,273 days for patients with hyperhidrosis.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.782 ± 0.129 | 0.799 ± 0.115 |
| Change from Baseline at SV1 (N=58, 60) | 0.010 ± 0.136 | -0.000 ± 0.124 |
Cerebral Palsy is a disability resulting in muscular incoordination and speech disturbances. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 925 days for patients with cerebral palsy.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.712 ± 0.131 | 0.733 ± 0.117 |
| Change from Baseline at SV1 (N=0, 8) | NA ± NA | 0.018 ± 0.114 |
Adult Focal Spasticity is a condition in which muscles are continuously tight or stiff in a certain area. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,562 days for patients with adult focal spasticity.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.621 ± 0.111 | 0.635 ± 0.124 |
| Change from Baseline at Week 4 (N=114, 201) | 0.002 ± 0.096 | 0.008 ± 0.096 |
Facial nerve disorder is a condition causing twitching, weakness or paralysis of the face. The SF-12 consists of 12 questions on various health questions. Health utility is a numerical indicator of a person's preferences for a given health state or health outcome. Health utility is a sub-score ranging from 0 (death) to 1 (perfect health) and is calculated from the SF-12 total score based on the following items: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 765 days for patients with facial nerve disorder.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.770 ± 0.134 | 0.759 ± 0.134 |
| Change from Baseline at SV1 (N=30, 63) | 0.035 ± 0.158 | 0.002 ± 0.111 |
"Other" disorders include focal dystonia (involuntary muscular contractions/abnormal postures), headache, pain, tics (sudden, repetitive, nonrhythmic movements/vocalizations), tremors (unintentional, rhythmic muscle movements), and other nonspecified disorders. The SF-12 is 12 questions on various health questions. Health utility is a numerical indicator of a person's preference for a given health state or health outcome. Health utility is a sub-score ranging from 0(death) to 1(perfect health) calculated from the SF-12 total score based on: physical functioning, role participation, social functioning, bodily pain, mental health, and vitality and is termed SF-6D. A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening. The length of time between Baseline and SV1 is scheduled at the physician's discretion and was a maximum of 568 days for patients with "other" disorders.
| Scores on a Scale | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 0.570 ± 0.137 | 0.610 ± 0.118 |
| Change from Baseline at SV1 (N=33, 72) | 0.060 ± 0.086 | 0.028 ± 0.113 |
Cervical dystonia is a condition in which the neck muscles contract involuntarily, causing the head to turn to one side, forward or backward. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 505 days for patients with cervical dystonia.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 154.8 ± 61.1 | 242.7 ± 99.6 |
| SV1 (N=37, 187) | 169.9 ± 70.2 | 246.4 ± 101.7 |
Blepharospasm is a condition in which the eyelids blink/close involuntarily. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 542 days for patients with blepharospasm.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 42.9 ± 13.8 | 67.3 ± 54.3 |
| SV1 (N=23, 54) | 47.8 ± 22.7 | 61.9 ± 39.5 |
Hyperhidrosis is a condition causing excessive sweating, regardless of temperature or exercise. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,273 days for patients with hyperhidrosis.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 192.5 ± 60.4 | 203.6 ± 74.8 |
| SV1 (N=80, 97) | 186.9 ± 53.8 | 206.5 ± 81.6 |
Adult Focal Spasticity is a condition in which muscles are continuously tight or stiff in a certain area. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 1,562 days for patients with adult focal spasticity.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 253.0 ± 132.6 | 346.4 ± 157.4 |
| SV1 (N=127, 225) | 295.4 ± 152.4 | 355.8 ± 150.2 |
Cerebral Palsy is a disability resulting in muscular incoordination and speech disturbances. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 925 days for patients with cerebral palsy.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 260.0 ± 89.4 | 245.5 ± 101.1 |
| SV1 (N=1, 12) | 200.0 ± NA | 252.5 ± 105.2 |
Facial nerve disorder is a condition causing twitching, weakness or paralysis of the face. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 765 days for patients with facial nerve disorder.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 31.3 ± 13.7 | 40.6 ± 25.4 |
| SV1 (N=31, 69) | 30.9 ± 13.4 | 44.1 ± 31.2 |
"Other" disorders include focal dystonia (involuntary muscular contractions/abnormal postures), headache, pain, tics (sudden, repetitive, nonrhythmic movements/vocalizations), tremors (unintentional, rhythmic muscle movements), and other nonspecified disorders. The BOTOX® dose was assessed in this patient population. The length of time between Baseline and Subsequent Visit 1 (SV1) is scheduled at the physician's discretion and was a maximum of 568 days for patients with "other" disorders.
| Units | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Baseline | 157.2 ± 82.4 | 187.2 ± 106.8 |
| SV1 (N=40, 75) | 173.4 ± 106.9 | 185.7 ± 110.1 |
Resource utilization patterns are assessed in terms of concurrent procedures utilized during the study (up to 1,785 days across all indications) and are grouped by highest level term. (Note: NEC=not elsewhere classified)
| Patients | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Bone and joint therapeutic procedures | 0 | 3 |
| Economic and housing issues | 2 | 1 |
| Eye therapeutic procedures | 1 | 0 |
| Lifestyle issues | 3 | 9 |
| Therapeutic procedures and supportive care NEC | 41 | 69 |
Resource utilization patterns are assessed in terms of concurrent surgical procedures utilized during the study (up to 1,785 days across all indications) and are grouped by highest level term. (Note: NEC=not elsewhere classified)
| Patients | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| Bone and joint therapeutic procedures | 2 | 6 |
| Eye therapeutic procedures | 1 | 2 |
| Gastrointestinal therapeutic procedures | 0 | 1 |
| Head and neck therapeutic procedures | 0 | 1 |
| Nervous system, skull&spine therapeutic procedures | 2 | 6 |
| Renal/urinary tract investigations & urinalyses | 1 | 0 |
| Renal and urinary tract therapeutic procedures | 0 | 1 |
| Skin appendage conditions | 0 | 1 |
| Soft tissue therapeutic procedures | 2 | 6 |
| Therapeutic procedures and supportive care NEC | 1 | 1 |
| Vascular therapeutic procedures | 0 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Naïve to Botox® Treatment | — | 5/506 (1%) | 0/506 (0%) |
| Non-naïve to Botox® Treatment | — | 33/866 (3.8%) | 0/866 (0%) |
| Event | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment |
|---|---|---|
| DeathGeneral disorders | 1/506 | 6/866 |
| DysphagiaGastrointestinal disorders | 1/506 | 4/866 |
| AstheniaGeneral disorders | 0/506 | 2/866 |
| Hip FractureInjury, poisoning and procedural complications | 1/506 | 2/866 |
| Myocardial InfarctionCardiac disorders | 0/506 | 2/866 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/506 | 2/866 |
| DepressionPsychiatric disorders | 0/506 | 2/866 |
| Foot DeformityMusculoskeletal and connective tissue disorders | 1/506 | 0/866 |
| Multiple SclerosisNervous system disorders | 1/506 | 0/866 |
| Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/506 | 0/866 |
| Age, Customized(Participants) | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment | Total |
|---|---|---|---|
| 14 to 17 years | 22 | 28 | 50 |
| 18 to 65 years | 374 | 641 | 1015 |
| >65 years | 110 | 197 | 307 |
| Sex: Female, Male(Participants) | Naïve to Botox® Treatment | Non-naïve to Botox® Treatment | Total |
|---|---|---|---|
| Female | 304 | 577 | 881 |
| Male | 202 | 289 | 491 |
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan